Abstract
A patient with disseminated osseous metastases due to breast cancer reported multifocal pain. Because of persisting pain after a first cycle of chemotherapy, 1,295 MBq Re-186 HEDP was administered intravenously. Excellent pain relief was observed. Subsequently, the patient received further combined chemotherapy and Re-186 HEDP therapy and remained pain free. Tc-99m MDP bone imaging showed a significant regression of osseous metastases. It may be speculated that the combination of Re-186 HEDP and chemotherapy results in significantly increased palliation of metastatic bone disease.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bone Neoplasms / diagnostic imaging
-
Bone Neoplasms / secondary*
-
Bone Neoplasms / therapy*
-
Breast Neoplasms / pathology*
-
Carcinoma, Ductal, Breast / secondary
-
Carcinoma, Ductal, Breast / therapy
-
Combined Modality Therapy
-
Etidronic Acid / therapeutic use*
-
Female
-
Humans
-
Middle Aged
-
Palliative Care / methods*
-
Radioisotopes / therapeutic use*
-
Radionuclide Imaging
-
Radiopharmaceuticals / therapeutic use
-
Rhenium / therapeutic use*
-
Technetium Tc 99m Medronate
Substances
-
Radioisotopes
-
Radiopharmaceuticals
-
Rhenium
-
Etidronic Acid
-
Technetium Tc 99m Medronate